The disclosure provides methods of using inhibitors of chaperone proteins, such as HSP90 inhibitors, in combination with agents that increase proteotoxic stress on tumor cells or agents that induce a biochemical rewiring of the chaperome. The proteotoxic agents are administered prior to administration of the chaperone proteins to achieve synergistic activity.本揭示內容提供使用伴護蛋白(chaperone protein)之抑制劑(例如HSP90抑制劑)與增加對腫瘤細胞之蛋白毒性壓力之藥劑或誘導伴護蛋白體(chaperome)之生物化學重新佈局之藥劑之組合的方法。該等蛋白毒性劑係在投與該等伴護蛋白之前投與以達成協同活性。
